The cloning and characterization of TOAD-64: a gene expressed transiently during neuronal differentiation in the mammalian nervous system

During the development of the mammalian central nervous system, a pool of morphologically homogeneous, mitotically active progenitor cells in the neural tube gives rise to the enormously diverse population of postmitotic cells that assume the properties of neurons or glia. Postmitotic neurons elaborate processes that are involved in the migration of neurons to their adult positions as well as the elaboration of axonal and dendritic arbors that will ultimately form specific synaptic contacts. The generation of postmitotic neurons from precursor cells is a central differentiative event in development, but molecular markers of this event are few.Using 2D gel electrophoresis, proteins that are developmentally regulated over the course of neurogenesis were identified. One of these, TOAD-64 (Turned On After Division, 64kDa) is expressed by neurons immediately after their birth, and is dramatically down-regulated in the adult.The expression of the TOAD-64 protein and gene is coincident with initial neuronal differentiation and down regulated when the majority of axon growth is complete. TOAD-64 is up-regulated following neuronal induction of P19 and PC12 cells; it is re-expressed in adult spinal motor neurons following axotomy of the sciatic nerve; and is present on the lamellipodia and filopodia of growth cones.The gene encoding TOAD-64 shows sequence homology to the unc-33 gene of C. elegans, mutations in which lead to aberrations in axon outgrowth. A chick homolog (CRMP-62) of TOAD-64 has also recently been cloned, and appears to mediate growth cone collapse in response to collapsin, suggesting a similar role for TOAD-64 in the rat.Taken together these results suggest that TOAD-64 may be a central element in the processes underlying axonal outgrowth and pathfinding

Incorporation of Genetic Pathway Information into Analysis of Multivariate Gene Expression Data

Abstract: Multivariate microarray gene expression data are commonly collected to study the genomic responses under ordered conditions such as over increasing/decreasing dose levels or over time during biological processes. One important question from such multivariate gene expression experiments is to identify genes that show different expression patterns over treatment dosages or over time and pathways that are perturbed during a given biological process. In this paper, we develop a hidden Markov random field model for multivariate expression data in order to identify genes and subnetworks that are related to biological processes, where the dependency of the differential expression patterns of genes on the networks are modeled by a Markov random field. Simulation studies indicated that the method is quite effective in identifying genes and the modified subnetworks and has higher sensitivity than the commonly used procedures that do not use the pathway information, with similar observed false discovery rates. We applied the proposed methods for analysis of a microarray time course gene expression study of TrkA- and TrkB-transfected neuroblastoma cell lines and identified genes and subnetworks on MAPK, focal adhesion and prion disease pathways that may explain cell differentiation in TrkA-transfected cell lines

Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries

Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs) and long-term survivors (LTSs). Materials and Methods Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia. Results Among 1,130 pediatric and young adults with radiographically confirmed DIPG, 122 (11%) were excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years). Median survival time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with STSs, more commonly presented at age < 3 or > 10 years (11% v 3% and 33% v 23%, respectively; P < .001) and with longer symptom duration ( P < .001). STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, respectively; P = .008), ring enhancement (38% v 23%, respectively; P = .007), necrosis (42% v 26%, respectively; P = .009), and extrapontine extension (92% v 86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002). Conclusion We report clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clinical trials

Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study

Limited therapies exist for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN). For this reason, the activity of vinblastine (VBL) and methotrexate (MTX) was evaluated in children and young adults with NF1 and PN. Patients ≤ 25 years of age with progressive and/or inoperable NF1-PN received VBL 6 mg/m2 and MTX 30 mg/m2 weekly for 26 weeks, followed by every 2 weeks for 26 weeks. Objective response rate was the primary endpoint. Of 25 participants enrolled, 23 were evaluable. The median age of participants was 6.6 years (range 0.3–20.7). The most frequent toxicities were neutropenia and elevation of transaminases. On two-dimensional (2D) imaging, 20 participants (87%) had stable tumor, with a median time to progression of 41.5 months (95% confidence interval 16.9, 64.9). Two of eight participants (25%) with airway involvement demonstrated functional improvements including decreased positive pressure requirements and apnea-hypopnea index. A post hoc three-dimensional (3D) analysis of PN volumes was completed on 15 participants with amenable imaging; 7 participants (46%) had progressive disease on or by the end of therapy. VBL/MTX was well-tolerated but did not result in objective volumetric response. Furthermore, 3D volumetric analysis highlighted the lack of sensitivity of 2D imaging for PN response evaluation